Piper Sandler Maintains Overweight on Paycom Software, Raises Price Target to $622

Piper Sandler analyst Arvind Ramnani maintains Paycom Software (NYSE:PAYC) with a Overweight and raises the price target from $472 to $622.

byBenzinga Newsdesk

November 3, 2021

1 minute read

Piper Sandler analyst Arvind Ramnani maintains Paycom Software (NYSE:PAYC) with a Overweight and raises the price target from $472 to $622.

Quanta Services Stock Gains On Beating Q2 Estimates, Raised FY21 Outlook

By Akanksha

Today, 3:17 AM

Quanta Services Inc (NYSE:PWR) reported second-quarter revenue growth of 19.7% year-over-year to $3 billion, beating the consensus of $2.98 billion. Adjusted…

PWR

BMO Capital Maintains Outperform on Verve Therapeutics, Raises Price Target to $62

By Benzinga Newsdesk

Today, 3:17 AM

BMO Capital analyst Kostas Biliouris maintains Verve Therapeutics (NASDAQ:VERV) with a Outperform and raises the price target from $48 to $62.

VERV

Arbutus Biopharma: Q1 Earnings Insights

By Benzinga Insights

Today, 3:17 AM

Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

ABUS

Calyxt Announced Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients

By Charles Gross

Today, 3:17 AM

Calyxt, Inc. (Nasdaq: CLXT) today announced that it has signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to further develop and scale Calyxt's proprietary Plant Cell Matrix™ (PCM™) technology platform.

CLXT

Piper Sandler Maintains Overweight on Paycom Software, Raises Price Target to $622

Related Posts

Quanta Services Stock Gains On Beating Q2 Estimates, Raised FY21 Outlook

BMO Capital Maintains Outperform on Verve Therapeutics, Raises Price Target to $62

Arbutus Biopharma: Q1 Earnings Insights

Calyxt Announced Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients